Dr. David Michael Nanus, M.D. of Weill Cornell Medicine discusses the agents currently available or in research pipelines than target molecular abnormalities in CRPC at ASCO GU 2016 in San Francisco.
Advertisement
[the_ad id="32629"]
Agents currently available or in research pipelines than target molecular abnormalities in CRPC
By Editor